Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and admin

Change in fair value of acquisition consideration

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Twist Bioscience Corp

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. Its products include genes, oligo pools, Next Generation Sequencing (NGS), variant libraries, synthetic controls, antibody discovery, and SARS-CoV-2 Tools. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment consists of Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck on February 4, 2013 and is headquartered in San Francisco, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Twist Bioscience Corp meets Q1 expectations, eyes growth opportunities

Twist Bioscience Corp's Q1 performance met or exceeded expectations across key revenue segments, with a focus on expanding customer base and improving turnaround times.
While facing challenges such as COVID impact on China sales and margin dips due to fixed costs, the company aims for revenue growth and improved margins through strategic execution.
The company's strengths lie in strong gross margins, record bookings in NGS, and efforts towards DNA data storage alliances, positioning for future growth and innovation.
Opportunities include continued customer expansion, Fast Gene market development, and revenue growth driven by NGS and SynBio performance, amidst a value-based pricing strategy.

Twist Bioscience Corp achieves $60.2M revenue in Q2 2023

Twist Bioscience Corp's Q2 2023 earnings call highlighted strong revenue growth, cost reduction efforts, and a focus on achieving profitability. The company is navigating challenges in the biopharma sector while leveraging strengths in technology and sales execution for future growth.

Twist Bioscience Corp reports record Q3 revenue, focuses on growth

Twist Bioscience Corp delivered a strong performance in Q3, with record revenue and strategic product launches driving growth across key segments.
While facing challenges in biopharma revenue and commercial execution, the company is focused on expansion, talent acquisition, and cost management to drive future growth.
With a clear focus on innovation, market expansion, and achieving profitability milestones, Twist Bioscience Corp is well-positioned for future success and market leadership.
The company's strengths in SynBio products, strategic market positioning, and stable funding outlook underscore its potential for sustained growth and value creation.

Twist Bioscience Corp reports robust revenue growth and eyes profitability

Twist Bioscience Corp's Q4 2023 earnings call highlighted strong revenue growth, operational efficiency, and a solid financial position.
The company faces challenges in managing expenses and achieving profitability but sees opportunities in revenue growth and market expansion.
By leveraging strengths in product launches, customer relationships, and revenue growth, Twist Bioscience aims for continued success and margin expansion in fiscal 2024.

Twist Bioscience Corp excels in Q1 2024, focuses on growth

Twist Bioscience Corp's Q1 2024 earnings call highlighted robust revenue growth, margin expansion, and strategic focus on operational efficiency. The company's emphasis on customer needs, premium pricing, and cost efficiency positions it well for future growth and profitability.

Twist Bioscience reports robust Q2 revenue growth and margin targets

Twist Bioscience Corp delivered strong revenue growth and aims for margin improvement, driven by successful product lines and strategic initiatives.
While facing challenges in managing expenses and achieving profitability, the company is well-positioned to leverage market opportunities and regulatory advantages.
With a focus on innovation, market expansion, and margin growth, Twist is poised for continued success and competitive growth in the biopharma sector.
Navigating operational challenges and seizing growth opportunities will be crucial for Twist Bioscience to achieve its financial targets and sustain market leadership.

Twist Bioscience Corp reports robust Q3 revenue growth and profitability outlook

Twist Bioscience Corp delivered strong revenue growth and operational performance in Q3 2024, driven by robust NGS and biopharma revenue streams.
While facing challenges in achieving profitability targets, the company's focus on margin improvement and capacity expansion positions it for future growth.
Guidance for fiscal 2024 indicates promising revenue growth, highlighting opportunities for sustained expansion and enhanced financial performance.

Twist Bioscience Corp reports record revenue and aims for profitability

Twist Bioscience Corp delivered strong financial performance, with record revenue and margin growth driven by key product segments and operational efficiencies.
The company's focus on achieving adjusted EBITDA profitability and cash flow positivity, along with robust fiscal 2025 guidance, signals a path towards sustainable growth.
While challenges like cost management and market competition persist, opportunities in market traction, revenue diversification, and innovation position the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, is proud to be Certified™ by Great Place to Work®. The prestigious award is based entirely on what current employees say about their experience working at Twist Bioscience. Great Place to Work® is the global authority on workplace culture, employee experience and the leadership behaviors proven to de

Twist Bioscience Earns 2021 Great Place to Work Certification™

SOUTH SAN FRANCISCO, Calif. & LA JOLLA, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it signed a partnership agreement with Kyowa Kirin Pharmaceutical Research, Inc., a subsidiary of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company, to discover novel antibodies for therapeutic use against an

Twist Bioscience and Kyowa Kirin Partner for GPCR Antibody Discovery

Fate Therapeutics

These biotech companies are small, but they have tremendous growth prospects.

2 Under-the-Radar Stocks Cathie Wood Loves That Could Be Huge Winners

Shares of Twist Bioscience Corp. were down 1.6% in premarket trading on Wednesday after the company said its in-vitro diagnostic test that can detect SARS-CoV-2 RNA received emergency authorization in the U.S. Twist's test can identify the presence of the virus from a patient sample; it can also be used by Biotia Inc.'s software system to analyze the sequence and detect any genetic variants. So-called "variants of concern" have emerged over the last six months, including the B.1.1.7 variant out of the U.K., which is thought to be more infectious and makes up to 30% of all new U.S. cases, according to the Centers for Disease Control and Prevention.

Twist's COVID-19 test, which can detect variants, gets authorized

SOUTH SAN FRANCISCO, Calif. & NEW YORK--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Biotia, Inc., a company that uses proprietary analytical software for infectious disease diagnostics, today received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 Next-Generation Sequencing (NGS) Assay. The SARS-CoV-2

Twist Bioscience and Biotia Receive U.S. FDA Emergency Use Authorization for First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay

Trimble

Sure, the ARK Invest CIO likes Tesla, but there are other stocks you might not know about.

2 Under-the-Radar Nasdaq Stocks Cathie Wood Loves Right Now

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced positive preclinical data demonstrating that GLP-1R antibodies identified from its proprietary G-protein coupled receptor (GPCR) libraries showed potent blood glucose control. Glucagon-like peptide-1 receptor (GLP-1R) is a class B GPCR that acts as the receptor for the inc

Twist Bioscience Functional GLP-1R Antibodies Identified From Its Proprietary Synthetic DNA GPCR Libraries Demonstrate Potent Blood Glucose Control

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist began shipping its new synthetic RNA reference controls, including B.1.351 and P.1, that have emerged in South Africa and Brazil, respectively.

Twist Bioscience Begins Shipping of Synthetic RNA Controls for B.1.351 and P.1 Variants

Twist Biosciences (TWST) is a biology company developing a breakthrough synthetic DNA technology that has the potential to change the world. The post A Golden Buying Opportunity Amid the Recent Tech Sector Meltdown appeared first on InvestorPlace.

A Golden Buying Opportunity Amid the Recent Tech Sector Meltdown

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, has been named to Fast Company's prestigious annual list of the World's Most Innovative Companies (MIC) for 2021. The list honors the businesses that have not only found a way to be resilient in the past year, but also those who have turned challenges into impact-making processes. These c

Twist Bioscience Named to Fast Company's Annual List of the World's Most Innovative Companies for 2021

SOUTH SAN FRANCISCO, Calif. & BOULDER, Colo.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Watchmaker Genomics today announced a broad partnership to enable innovative research across a wide range of high throughput sequencing applications including oncology and tumor profiling, inherited disease detection, liquid biopsy assays, and minimal residual disease

Twist Bioscience and Watchmaker Genomics Announce Partnership to Drive New Applications of High-throughput Genetic Sequencing

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced several events at the virtual 2021 Advances in Genome Biology and Technology (AGBT) meeting to be held March 1-3, 2021. During the conference, Twist will host a workshop with customer presentations from Regeneron Genetics Center and HelioHealth; Twist will present a poster

Twist Bioscience to Highlight Genotyping by Sequencing and Methylation Solution During AGBT

Twist Bioscience Corp (NASDAQ: TWST) has launched its NGS Methylation Detection System, end-to-end sample preparation, and target enrichment solution for identifying methylated regions in the human genome. DNA methylation plays a key role in many biological processes, including cancer.

Twist Bioscience Launches Methylation Detection Systems

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of the Twist NGS Methylation Detection System, a robust, end-to-end sample preparation and target enrichment solution for identifying methylated regions in the human genome. DNA methylation plays a key role in many biological processes including cancer. When pre

Twist Bioscience Launches Industry-Leading NGS Methylation Detection System for Liquid Biopsy Cancer Analysis and Epigenetic Studies

ARK Genomic Revolution Multi-Sector ETF

ARK Innovation ETF

ARK Industrial Innovation ETF

Novartis

Pacific Biosciences of California

Regeneron Pharmaceuticals

Roche Holding AG

Takeda Pharmaceutical

Teladoc

Thermo Fisher Scientific

Vertex Pharmaceuticals

Cathie Wood and her team have shown investors that they have the capability to turn double-digit growth dreams into reality.

ARKG: Precautionary Measures, But Transformational Objectives Remain Intact

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Berry Genomics, a leading commercial next-generation sequencing (NGS) provider in China, will add Twist's NGS target enrichment and library preparation tools to its offering. The product offering combines the genomic and next generation sequencing expertise of Berry G

Twist Bioscience and Berry Genomics to Offer New NGS Solution to Advance Research and Precision Medicine

Twist Bioscience Corp (NASDAQ: TWST) and Victorian Clinical Genetic Services (VCGS) have developed a novel whole-exome capture assay, which utilizes Next Generation Sequencing to conduct analysis and sequencing of the entire exome. In particular, the assay can target difficult to cover, non-coding regions outside the normal exome known to contain pathogenic variants.

Twist Bioscience Collaborates With Australia Based Specialist Provider For Whole Exome Capture Assay

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Victorian Clinical Genetic Services (VCGS), an Australian-based specialist provider of prenatal, childhood and adult genetics services, today announced that together they have developed a novel whole exome capture assay. The assay, which utilizes Next Generation Sequencing (NGS) to co

Twist Bioscience and Victorian Clinical Genetic Services Collaborate on Development of Novel Whole Exome Capture Diagnostic Assay

Celsius Holdings

Green Brick Partners

Taiwan Semiconductor Manufacturing

These stocks look ripe for a 2021 breakout. Seeking Alpha Top Stocks makes it easy to find the strongest stocks in the market.

Which Stocks Look Ready To Breakout (Video)

Twist Bioscience Corporation (TWST) CEO Emily Leproust on Q1 2021 Results - Earnings Call Transcript

An analyst downgraded the stock despite its better-than-expected quarterly results.

Why Twist Bioscience Stock Is Tanking Today

Shares of Twist Bioscience (NASDAQ:TWST) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 28.00% over the past year to ($0.72), which beat the estimate of ($0.74).

Recap: Twist Bioscience Q1 Earnings

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the first quarter of fiscal 2021 ended December 31, 2020. “We reported a strong quarter both for orders and revenue, building a solid foundation for fiscal 2021,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Biosci

Twist Bioscience Reports First Quarter Fiscal 2021 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced several senior management promotions and team expansion. “Twist is growing at a significant rate, meeting and exceeding important milestones and building value. This can only be achieved with strong leadership and a dedicated workforce. The executive team promotions and ad

Twist Bioscience Announces Executive Team Appointments

Twist Bioscience (TWST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Twist Bioscience Corp Stock (TWST)